Search clinical trials for: Ipatasertib

Total 53 results

Genentech, Inc.

Completed

A Study Evaluating the Effect of Formulation on the Bioavailability of Ipatasertib in Healthy Volunteers

Healthy Volunteer

United States
Genentech, Inc.

Completed

Ipatasertib (GDC-0068) Study to Evaluate Formulation Change and Food Effect on Bioavailability in Healthy Subjects

Cancer

United States
Hoffmann-La Roche

Completed

A Study Of The Pharmacokinetics And Safety Of Ipatasertib In Chinese Participants With Locally Advanced Or Metastatic Solid Tumors.

Solid Tumors

China
Genentech, Inc.

Completed

A Study of Ipatasertib in Participants With Mild, Moderate or Severe Hepatic Impairment Compared to Healthy Participants

Hepatic Insufficiency

United States
Genentech, Inc.

Completed

A Study Evaluating the Safety, Tolerability, and Pharmacokinetics of GDC-0973 in Combination With GDC-0068 When Administered in Participants With Locally Advanced or Metastatic Solid Tumors

Neoplasms

United States, Spain
Institute of Cancer Research, United Kingdom
Hoffmann-La Roche

Recruiting

A Trial of Ipatasertib in Combination With Atezolizumab (IceCAP)

Solid Tumor | Glioblastoma Multiforme | Prostate Cancer Metastatic

United Kingdom
SOLTI Breast Cancer Research Group
Roche Pharma AG

Recruiting

Ipatasertib + Pertuzumab +Trastuzumab in Advanced HER2+ PI3KCA-mutant Breast Cancer Patients (IPATHER)

Metastatic Breast Cancer

Spain
Jun Zhang, MD, PhD
University of Iowa; University of Kentucky

Recruiting

Ipatasertib and Docetaxel in Metastatic NSCLC Patients Who Have Failed 1st Line Immunotherapy (Ipat-Lung)

NSCLC Stage IV | NSCLC Stage IIIB

United States
Hoffmann-La Roche

Recruiting

A Rollover Study for Participants Previously Enrolled in a Genentech and/or F. Hoffman-La Roche Sponsored Study (UmbrellaMAX)

Cancer

Korea, Republic of, United Kingdom, Japan, Costa Rica, Belgium, Taiwan, Russian Federation, Mexico, Poland, France
Hoffmann-La Roche

Completed

A Study of Ipatasertib in Combination With Atezolizumab and Paclitaxel as a Treatment for Participants With Locally Advanced or Metastatic Triple-Negative Breast Cancer

Triple-Negative Breast Cancer

Israel, United States, Australia, Korea, Republic of, Belgium, Argentina, Denmark, Finland, Italy, Portugal, Spain, Taiwan, Thailand, Japan, United Kingdom, Brazil, Canada, Colombia, Mexico, France, Costa Rica, Switzerland, Czechia, P... and more
Genentech, Inc.

Completed

A Study Assessing the Safety and Efficacy of Adding Ipatasertib to Paclitaxel Treatment in Participants With Breast Cancer That Has Spread Beyond the Initial Site, and the Cancer Does Not Have Certain Hormonal Receptors (LOTUS)

Breast Neoplasms

United States, Spain, Korea, Republic of, Taiwan, Italy, Singapore, France, Belgium
Genentech, Inc.
SOLTI Breast Cancer Research Group

Completed

A Study of Ipatasertib (GDC-0068) in Combination With Paclitaxel as Neoadjuvant Treatment for Participants With Early Stage Triple Negative Breast Cancer

Breast Cancer

United States, Spain, Portugal
Royal Marsden NHS Foundation Trust
Pfizer; Hoffmann-La Roche

Recruiting

Fulvestrant, Ipatasertib and CDK4/6 Inhibition in Metastatic ER+/HER2- Breast Cancer Patients Without ctDNA Suppression (FAIM)

Advanced Breast Cancer | Metastatic Breast Cancer | ER+ Breast Cancer

United Kingdom
Icahn School of Medicine at Mount Sinai

Withdrawn

To Evaluate the Safety and Efficacy of Ipatasertib (GDC-0068) in Combination With Paclitaxel in Platinum-resistant Recurrent Epithelial Ovarian Cancer

Ovarian Neoplasms

United States
Hoffmann-La Roche

Completed

A Study Evaluating the Safety, Pharmacokinetics and Efficacy of Ipatasertib Administered in Combination With Rucaparib in Participants With Advanced Breast, Ovarian Cancer, and Prostate Cancer.

Breast Cancer | Ovarian Cancer | Prostate Cancer

United States, Korea, Republic of, Italy, Australia, Spain
Hoffmann-La Roche

Completed

A Study of Ipatasertib in Combination With Paclitaxel as a Treatment for Participants With PIK3CA/AKT1/PTEN-Altered, Locally Advanced or Metastatic, Triple-Negative Breast Cancer or Hormone Receptor-Positive, HER2-Negative Breast Cancer (IPATunity130)

Breast Cancer

United States, Korea, Republic of, Canada, United Kingdom, Australia, Belgium, Brazil, France, Slovenia, Spain, Taiwan, Japan, Italy, Argentina, India, Germany, Hungary, Russian Federation, Singapore, Ukraine, Costa Rica, Czechia, G... and more
Queen Mary University of London
Hoffmann-La Roche; Asan Medical Center; Kliniken Essen-Mitte; MedSIR

Active, not recruiting

Pre-operative Immunotherapy Combination Strategies in Breast Cancer (ECLIPSE)

Breast Cancer | Estrogen Receptor-positive Breast Cancer

United Kingdom
Medical Research Council
Merck Sharp & Dohme LLC; Aarhus University Hospital; NCRI Clinical Studies Groups and other collaborators

Unknown

Evaluation Of The Treatment Effectiveness Of Glioblastoma / Gliosarcoma Through The Suppression Of The PI3K/Akt Pathway In Compared With MK-3475

Glioblastoma

United States, Italy, Belgium, Germany, Poland, Russian Federation, Spain, Switzerland, Ukraine, United Kingdom
Hospices Civils de Lyon

Recruiting

Personalized Targeted IMMUNOtherapy-based Regimens in Recurrent GASTric Adenocarcinoma (IMMUNOGAST) (IMMUNOGAST)

Gastric Adenocarcinoma | Metastatic Gastric Cancer | Advanced Gastric Carcinoma | Metastatic Adenocarcinoma

France
Hoffmann-La Roche

Completed

A Study to Evaluate the Safety and Efficacy of Ipatasertib in Combination With Atezolizumab and Paclitaxel or Nab-Paclitaxel in Participants With Locally Advanced or Metastatic Triple-Negative Breast Cancer

Breast Cancer

France, United States, Spain, United Kingdom, Australia
MedSIR
Hoffmann-La Roche

Completed

Ipatasertib Plus Non-Taxane Chemotherapy for Advanced or Metastatic Triple-Negative Breast Cancer (PATHFINDER)

Triple Negative Breast Cancer

Spain, Portugal
Hoffmann-La Roche

Terminated

A Study Evaluating The Safety, Efficacy and Pharmacokinetics Of Ipatasertib In Combination With Atezolizumab And Docetaxel In Metastatic Castration-Resistant Prostate Cancer (mCRPC).

Castration-Resistant Prostatic Cancer

Spain, France, Switzerland, Italy
David VanderWeele

Terminated

Neoadjuvant Androgen Deprivation, Darolutamide, and Ipatasertib in Men With Localized, High Risk Prostate Cancer (ADDItion)

Castrate Resistant Prostate Cancer

United States
Canadian Cancer Trials Group
Canadian Cancer Clinical Trials Network; BC Cancer Foundation

Active, not recruiting

Prostate Cancer Biomarker Enrichment and Treatment Selection

Prostate Cancer

Canada
Genentech, Inc.

Completed

A Study of Ipatasertib (GDC-0068) in Combination With Fluoropyrimidine Plus Oxaliplatin in Participants With Advanced or Metastatic Gastric or Gastroesophageal Junction Cancer

Gastric Cancer

Spain, Korea, Republic of, Italy, United Kingdom, United States, Singapore, Taiwan, Germany, Malaysia, Hong Kong, France
Canadian Cancer Trials Group
Hoffmann-La Roche

Recruiting

Fulvestrant and Ipatasertib for Advanced HER-2 Negative and Estrogen Receptor Positive (ER+) Breast Cancer Following Progression on First Line CDK 4/6 Inhibitor and Aromatase Inhibitor (FINER)

Breast Cancer

Canada, Australia, New Zealand
Genentech, Inc.

Completed

Study of Ipatasertib or Apitolisib With Abiraterone Acetate Versus Abiraterone Acetate in Participants With Castration-Resistant Prostate Cancer Previously Treated With Docetaxel Chemotherapy

Prostate Cancer

United States, Spain, Czechia, France, Greece, Netherlands, United Kingdom, Romania, Italy
Hoffmann-La Roche

Completed

A Study to Evaluate the Effect of a Potent Cytochrome P450 (CYP) 3A Inhibitor on Ipatasertib

Healthy Volunteers

United States
Genentech, Inc.

Completed

Safety and Clinical Pharmacology of GDC-0068 in Combination With Docetaxel, Fluoropyrimidine Plus Oxaliplatin, Paclitaxel, or Enzalutamide in Participants With Advanced Solid Tumors

Neoplasms

United States, Spain, United Kingdom, France
Hoffmann-La Roche

Active, not recruiting

Ipatasertib Plus Abiraterone Plus Prednisone/Prednisolone, Relative to Placebo Plus Abiraterone Plus Prednisone/Prednisolone in Adult Male Patients With Metastatic Castrate-Resistant Prostate Cancer (IPATential150)

Metastatic Prostate Cancer

United States, Belgium, France, United Kingdom, Canada, Korea, Republic of, China, Denmark, Greece, Ireland, Portugal, Spain, Italy, Brazil, Mexico, Australia, Thailand, Japan, Costa Rica, Israel, Russian Federation, Austria, Hungary, Norwa... and more
Hoffmann-La Roche

Terminated

A Study of Ipatasertib Plus Palbociclib and Fulvestrant Versus Placebo Plus Palbociclib and Fulvestrant in Hormone Receptor Positive and HER2 Negative Locally Advanced Unresectable or Metastatic Breast Cancer (IPATunity150)

Breast Cancer

United States, Brazil, Australia, Canada, Japan, Korea, Republic of, Spain, United Kingdom
Queen Mary University of London
Hoffmann-La Roche; MedSIR; Westdeutsche Studiengruppe GmbH (WSG)

Active, not recruiting

Investigate the Contribution of Ipatasertib to Neoadjuvant Chemotherapy Plus Atezolizumab in TNBC (BARBICAN)

Triple Negative Breast Cancer

United Kingdom
Massachusetts General Hospital
Genentech, Inc.

Active, not recruiting

AKT Inhibitor, Ipatasertib, With Endocrine and CDK 4/6 Inhibitor for Patients With Metastatic Breast Cancer (TAKTIC)

Breast Cancer

United States
German Cancer Research Center

Recruiting

CRAFT: The NCT-PMO-1602 Phase II Trial

Metastatic or Locally Advanced Malignancies

Germany
German Cancer Research Center

Recruiting

Genomics Guided Targeted Post-neoadjuvant Therapy in Patients With Early Breast Cancer (COGNITION-GUIDE)

Early-stage Breast Cancer

Germany
National Cancer Institute (NCI)
NRG Oncology

Recruiting

Testing the Addition of Ipatasertib to the Usual Chemotherapy Treatment (Paclitaxel and Carboplatin) for Stage III or IV Epithelial Ovarian Cancer

Ovarian Endometrioid Adenocarcinoma | Primary Peritoneal High Grade Serous Adenocarcinoma | Fallopian Tube Endometrioid Adenocarcinoma | Ovarian High Grade Serous Adenocarcinoma | Fallopian Tube High Grade Serous Adenocarcinoma | Primary Peritoneal Endometrioid Adenocarcinoma | Stage III Fallopian... and other conditions

United States
Hoffmann-La Roche
Foundation Medicine, Inc.

Active, not recruiting

A Phase II Randomized Study Comparing the Efficacy and Safety of Targeted Therapy or Cancer Immunotherapy Versus Platinum-Based Chemotherapy in Patients With Cancer of Unknown Primary Site (CUPISCO)

Cancer of Unknown Primary Site

United Kingdom, Korea, Republic of, France, Australia, Germany, Austria, Croatia, Denmark, Finland, Greece, Hungary, Italy, Portugal, Spain, Japan, Brazil, Colombia, Mexico, Romania, Czechia, Norway, Thailand, Switzerland, Turkey, Nethe... and more
National Cancer Institute (NCI)

Recruiting

Testing the Addition of an Anti-cancer Drug, Ipatasertib, to the Usual Immunotherapy Treatment (Pembrolizumab) in Patients With Recurrent or Metastatic Squamous Cell Cancer of the Head and Neck

Head and Neck Squamous Cell Carcinoma | Recurrent Head and Neck Squamous Cell Carcinoma | Recurrent Hypopharyngeal Squamous Cell Carcinoma | Recurrent Laryngeal Squamous Cell Carcinoma | Recurrent Oral Cavity Squamous Cell Carcinoma | Recurrent Oropharyngeal Squamous Cell Carcinoma | Metastatic... and other conditions

United States
Hoffmann-La Roche

Recruiting

Tumor-Agnostic Precision Immuno-Oncology and Somatic Targeting Rational for You (TAPISTRY) Platform Study

Solid Tumors

Belgium, United States, Australia, Canada, Japan, Korea, Republic of, United Kingdom, Germany, China, Puerto Rico, Israel, Singapore, Spain, Brazil, Portugal, South Africa, Denmark, Italy, Poland, Hong Kong, France, New Zealand, Net... and more
Hoffmann-La Roche

Recruiting

A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Participants With Breast Cancer

Inoperable, Locally Advanced or Metastatic, ER-positive Breast Cancer

United States, Korea, Republic of, Spain, Australia, Israel
Hoffmann-La Roche

Active, not recruiting

A Study of Multiple Immunotherapy-Based Treatment Combinations in Hormone Receptor (HR)-Positive Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Breast Cancer (MORPHEUS HR+BC)

Breast Neoplasms

United States, Israel, Korea, Republic of
Hoffmann-La Roche
Gilead Sciences; Seagen Inc.

Recruiting

A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Metastatic or Locally Advanced Breast Cancer (Morpheus-panBC)

Breast Cancer

Korea, Republic of, Spain, United States, Israel, United Kingdom, France, Australia, Germany
Fondazione per la Medicina Personalizzata

Active, not recruiting

The Rome Trial From Histology to Target: the Road to Personalize Target Therapy and Immunotherapy (ROME)

Breast Cancer | Non Small Cell Lung Cancer | Gastrointestinal Cancer | Other Cancer

Italy
City of Hope Medical Center
National Cancer Institute (NCI)

Completed

Ipatasertib in Combination With Carboplatin, Carboplatin/Paclitaxel, or Capecitabine/Atezolizumab in Treating Patients With Metastatic Triple Negative Breast Cancer

Anatomic Stage IV Breast Cancer AJCC v8 | Prognostic Stage IV Breast Cancer AJCC v8 | Metastatic Triple-Negative Breast Carcinoma

United States
National Cancer Institute (NCI)

Recruiting

Study of Chemotherapy Plus Ipatasertib for People With Solid Tumors With AKT Mutations, A ComboMATCH Treatment Trial

Locally Advanced Malignant Solid Neoplasm | Unresectable Malignant Solid Neoplasm | Metastatic Malignant Solid Neoplasm

United States
Hoffmann-La Roche

Recruiting

A Study Of Multiple Immunotherapy-Based Treatment Combinations In Participants With Metastatic Non-Small Cell Lung Cancer (Morpheus- Non-Small Cell Lung Cancer) (Morpheus Lung)

Carcinoma, Non-Small-Cell Lung

Korea, Republic of, France, Spain, Taiwan, United States, Israel, Australia, United Kingdom
Alliance Foundation Trials, LLC.
Eli Lilly and Company; Pfizer; Genentech, Inc.; Foundation Medicine

Recruiting

A Study of Targeted Agents for Patients With Recurrent or Persistent Endometrial Cancer (EndoMAP)

Endometrial Cancer

United States
Hoffmann-La Roche
GOG Foundation; European Network of Gynaecological Oncological Trial Groups...

Active, not recruiting

A Study Evaluating the Efficacy and Safety of Biomarker-Driven Therapies in Patients With Persistent or Recurrent Rare Epithelial Ovarian Tumors (BOUQUET)

Ovarian Cancer

United States, Korea, Republic of, France, Germany, Spain, Italy, Canada, Russian Federation, United Kingdom, Turkey, Australia, Czechia, Switzerland
Genentech, Inc.

Completed

A Study Evaluating Targeted Therapies in Participants Who Have Advanced Solid Tumors With Genomic Alterations or Protein Expression Patterns Predictive of Response (MyTACTIC)

Advanced Unresectable or Metastatic Solid Malignancy

United States
National Cancer Institute (NCI)
NRG Oncology

Recruiting

Testing the Addition of the AKT Inhibitor, Ipatasertib, to Treatment With the Hormonal Agent Megestrol Acetate for Recurrent or Metastatic Endometrial Cancers

Recurrent Endometrial Endometrioid Adenocarcinoma | Stage IV Uterine Corpus Cancer AJCC v8 | FIGO Grade 1 Endometrial Endometrioid Adenocarcinoma | FIGO Grade 2 Endometrial Endometrioid Adenocarcinoma | Metastatic Endometrial Endometrioid Adenocarcinoma

United States

Search clinical trials for: Ipatasertib

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Senegal

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations